Immune Disease | Tolerability

GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

GAMMAGARD LIQUID 10% formulated for a broad spectrum of patients, is the first 10% IVIG solution with the following unique combination of features:

No added sugars¹
For your patients with diabetes, GAMMAGARD LIQUID has no added glucose or any other sugars, and its sucrose-free formula¹ may help reduce the risk of renal dysfunction² - it is stabilized with glycine, a natural amino acid
No added sodium¹
GAMMAGARD LIQUID may be appropriate for patients with conditions requiring restricted sodium intake
No added preservatives¹
GAMMAGARD LIQUID may be appropriate for patients who have difficulty tolerating
some preservatives
Latex-free packaging¹
For your patients with allergic reactions to latex, GAMMAGARD LIQUID may be the appropriate choice

GAMMAGARD LIQUID 10% has an osmolality of 240 - 300 mOsmol/kg, which is similar to physiological osmolality.¹

GAMMAGARD LIQUID 10% has a low pH of 4.6–5.1.¹ Research shows that low pH levels of IVIGs can lower dimers and aggregates.³

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see Important Safety Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

To view PDFs, you will need Adobe® Acrobat® Reader® software.

1. GAMMAGARD LIQUID Immune Globulin Intravenous (Human) 10% [package insert]. Deerfield, IL. Baxter International Inc.; April 2005.
2. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis. 1996;28:451-453.
3. Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intranvenous immunoglobulin therapy: importance of pH and dimmer formation . Biologicals. 2003;31:277-286.

Sign Up Today